Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Sep. 30, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 50,300,847	$ 81,214,354
Prepaid expenses	3,772,643	3,293,285
Other current assets	909,561	823,620
Short term investments	11,160,442	17,539,902
TOTAL CURRENT ASSETS	66,143,493	102,871,161
Property and equipment, net	4,381,628	4,526,848
Intangible assets, net	23,960,017	24,824,116
Other assets	122,333	45,789
TOTAL ASSETS	94,607,471	132,267,914
CURRENT LIABILITIES
Accounts payable	7,542,498	5,031,706
Accrued expenses	3,834,269	5,376,119
Accrued payroll and benefits	1,395,004	3,824,062
Deferred revenue	65,625	103,125
Derivative liabilities	955,193	1,301,604
Capital lease obligation	219,349	217,548
Other current liabilities	46,407	46,407
TOTAL CURRENT LIABILITIES	14,058,345	15,900,571
LONG-TERM LIABILITIES
Capital lease obligation, net of current portion	430,665	540,792
Contingent consideration obligations	5,862,464	5,862,464
Other non-current liabilities	329,760	342,453
TOTAL LONG-TERM LIABILITIES	$ 6,622,889	$ 6,745,709
Commitments and contingencies
Arrowhead Pharmaceuticals, Inc. stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 15,652 shares issued and outstanding as of March 31,2016 and September 30,2015	$ 16	$ 16
Common stock, $0.001 par value; 145,000,000 shares authorized; 59,960,711 and 59,544,677 shares issued and outstanding as of March 31, 2016 and September 30, 2015, respectively	152,330	151,914
Additional paid-in capital	431,061,481	426,873,358
Accumulated other comprehensive income (loss)	59,913	(136,425)
Accumulated deficit	(356,792,315)	(316,712,041)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	74,481,425	110,176,822
Noncontrolling interest	(555,188)	(555,188)
TOTAL STOCKHOLDERS’ EQUITY	73,926,237	109,621,634
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 94,607,471	$ 132,267,914